PUBLICATION

Circulating Tumor Cells Characterization Revealed TIMP1 as a Potential Therapeutic Target in Ovarian Cancer

Authors
Abreu, M., Cabezas-Sainz, P., Alonso-Alconada, L., Ferreirós, A., Mondelo-Macía, P., Lago-Lestón, R.M., Abalo, A., Díaz, E., Palacios-Zambrano, S., Rojo-Sebastian, A., López-López, R., Sánchez, L., Moreno-Bueno, G., Muinelo-Romay, L.
ID
ZDB-PUB-210225-7
Date
2020
Source
Cells   9(5): (Journal)
Registered Authors
Keywords
TIMP1, cell plasticity, circulating tumor cells (CTCs), ovarian cancer
MeSH Terms
  • Adult
  • Aged
  • Aged, 80 and over
  • Animals
  • Cell Line, Tumor
  • Cell Plasticity
  • Cell Proliferation
  • Down-Regulation
  • Female
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Mice
  • Middle Aged
  • Molecular Targeted Therapy*
  • Neoplasm Invasiveness
  • Neoplastic Cells, Circulating/metabolism*
  • Neoplastic Cells, Circulating/pathology*
  • Ovarian Neoplasms/diagnosis
  • Ovarian Neoplasms/drug therapy*
  • Ovarian Neoplasms/enzymology*
  • Ovarian Neoplasms/genetics
  • Tissue Inhibitor of Metalloproteinase-1/metabolism*
  • Xenograft Model Antitumor Assays
  • Young Adult
  • Zebrafish
PubMed
32423054 Full text @ Cells
Abstract
Recent studies showed a relevant role of hematogenous spread in ovarian cancer and the interest of circulating tumor cells (CTCs) monitoring as a prognosis marker. The aim of the present study was the characterization of CTCs from ovarian cancer patients, paying special attention to cell plasticity characteristics to better understand the biology of these cells.
CTCs isolation was carried out in 38 patients with advanced high-grade serous ovarian cancer using in parallel CellSearch and an alternative EpCAM-based immunoisolation followed by RT-qPCR analysis to characterize these cells.
Epithelial CTCs were found in 21% of patients, being their presence higher in patients with extraperitoneal metastasis. Importantly, this population was characterized by the expression of epithelial markers as MUC1 and CK19, but also by genes associated with mesenchymal and more malignant features as TIMP1, CXCR4 and the stem markers CD24 and CD44. In addition, we evidenced the relevance of TIMP1 expression to promote tumor proliferation, suggesting its interest as a therapeutic target.
Overall, we evidenced the utility of the molecular characterization of EpCAM+ CTCs from advanced ovarian cancer patients to identify biomarkers with potential applicability for disseminated disease detection and as therapeutic targets such as TIMP1.
Genes / Markers
Figures
Show all Figures
Expression
Phenotype
Mutations / Transgenics
Human Disease / Model
Sequence Targeting Reagents
Fish
Antibodies
Orthology
Engineered Foreign Genes
Mapping